vimarsana.com
Home
Live Updates
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 : vimarsana.com
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19
WESTON, Fla. and ANN ARBOR, Mich., April 20, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions,
Related Keywords
Michigan ,
United States ,
Casey Mcdonald ,
Stepheng Marcus ,
Jon Nugent ,
Salim Hayek ,
Frankel Cardiovascular Center ,
University Of Michigan Health ,
Cantex Pharmaceuticals Inc ,
Kellogg Eye Center ,
University Of Michigan ,
Rogel Cancer Center ,
Prnewswire Cantex Pharmaceuticals Inc ,
Nasdaq ,
University Hospital ,
Tv Therapeutics Inc ,
Michigan Medicine ,
Medical Director ,
Michigan Health Frankel Cardiovascular Center ,
Chief Executive Officer ,
Cantex Pharmaceuticals ,
Um Medical ,
Um Medical School ,
Michigan Health ,
Von Voigtlander Women ,
Michigan Health West ,
Rogel Cancer ,
Covid 19 ,
vimarsana.com © 2020. All Rights Reserved.